Jefferies Starts Cabaletta Bio Inc. (CABA) at Buy, 'Strong PoC Supports Fast Pathway for CABA's CART in Autoimmune'

Jefferies analyst Kelly Shi initiates coverage on Cabaletta Bio Inc. (NASDAQ: CABA) with a Buy rating and a price target of $36.00.

The analyst comments "We view CABA as a leader in CART for autoimmune diseases. Co formed an exclusive partnership with Dr. Schett, who led the landmark CART study in SLE and add'l diseases using a near-identical CAR design, allows the lead asset '201 to quickly move forward in 4 indications simultaneously. Data from all 4 Ph1/2s in '24 ahead of competitors will be key near-term catalysts, and positive readouts could support an expedited regulatory path. We initiate at Buy & $36 PT."

For an analyst ratings summary and ratings history on Cabaletta Bio Inc. click here. For more ratings news on Cabaletta Bio Inc. click here.

Shares of Cabaletta Bio Inc. closed at $22.03 yesterday.

You May Also Be Interested In

• Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward